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Abstract
There is limited information on the serotypes causing non-invasive pneumococcal pneumonia (NIPP). Our aim was to
characterize pneumococci causing NIPP in adults to determine recent changes in serotype prevalence, the potential
coverage of pneumococcal vaccines and changes in antimicrobial resistance. Serotypes and antimicrobial susceptibility
profiles of a sample of 1300 isolates recovered from adult patients ($18 yrs) between 1999 and 2011 (13 years) were
determined. Serotype 3 was the most frequent cause of NIPP accounting for 18% of the isolates. The other most common
serotypes were 11A (7%), 19F (7%), 19A (5%), 14 (4%), 22F (4%), 23F (4%) and 9N (4%). Between 1999 and 2011, there were
significant changes in the proportion of isolates expressing vaccine serotypes, with a steady decline of the serotypes
included in the 7-valent conjugate vaccine from 31% (1999–2003) to 11% (2011) (P,0.001). Taking together the most recent
study years (2009–2011), the potential coverage of the 13-valent conjugate vaccine was 44% and of the 23-valent
polysaccharide vaccine was 66%. While erythromycin resistance increased from 8% in 1999–2003 to 18% in 2011 (P,0.001),
no significant trend was identified for penicillin non-susceptibility, which had an average value of 18.5%. The serotype
distribution found in this study for NIPP was very different from the one previously described for IPD, with only two
serotypes in common to the ones responsible for half of each presentation in 2009–2011 – serotypes 3 and 19A. In spite of
these differences, the overall prevalence of resistant isolates was similar in NIPP and in IPD.
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Introduction
Pneumonia is a common infection that causes high rates of
morbidity and mortality worldwide. Streptococcus pneumoniae
(pneumococcus) is thought to be the major cause of pneumonia,
responsible for up to half of all cases [1]. Only a small fraction of
pneumococcal pneumonias are bacteremic, with non-invasive
pneumococcal pneumonia (NIPP) estimated to be three to ten-
times more frequent than invasive pneumococcal pneumonia
[2,3]. While bacteremic pneumonia is a more severe form of
pneumonia, it is less clear if bacteremia can be considered an
independent predictor of mortality [4,5]. In adults, bacteremic
pneumonia accounts for most of the cases of invasive pneumo-
coccal disease (IPD). While the serotype distribution of IPD and
NIPP have been sometimes assumed to be the same [6], it is
becoming increasingly clear that this is not so [5,7]. This
observation is in agreement with the recognition that some
serotypes, and even different genetic lineages expressing the same
serotype, may have different invasive disease potentials [8], leading
to the expectation that less invasive serotypes would be more
abundantly represented in NIPP than in IPD.
In developed countries, pneumonia is believed to be a major
cause of morbidity among older adults, and, together with
influenza, is the leading cause of death from infectious disease in
the US considering the entire population [9]. Until recently, the
only available vaccine for adults was the 23-valent polysaccharide
vaccine (PPV23) that, while potentially effective in preventing
IPD, may be less efficacious against NIPP [10,11]. Possibly due to
the ongoing debate on the usefulness of PPV23 vaccination, in the
majority of the European countries, including Portugal, there has
been a low uptake of this vaccine [12,13]. On the other hand, the
7-valent conjugate vaccine (PCV7) was introduced in many
European countries for vaccinating children, rapidly reaching high
coverages in the targeted age groups. PCV7 was available in
Portugal for vaccination of children between 2001 and 2009 and,
although not part of the national immunization program, its
uptake was estimated to have grown continuously, albeit slower
that in countries where it was part of the national immunization
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program [14]. Changes in the serotype distribution of isolates
causing IPD, compatible with an effect of PCV7 occurred in both
children and adults in Portugal and elsewhere [13–17], the latter
potentially resulting from a herd effect. The 10-valent (PCV10)
and the 13-valent conjugate vaccines (PCV13) became available in
Portugal in 2009 and in 2010, respectively. In September 2011,
PCV13 received the European Medicines Agency approval for use
in adults $50 yrs and in July 2013 was approved for adults $
18 yrs, for the prevention of IPD. Currently PCV13 is approved
for all ages from 6 weeks up and there is now initial evidence of its
efficacy against pneumococcal pneumonia in adults caused by the
serotypes included in the vaccine [18].
The aim of this study was to determine the serotype distribution
and antimicrobial resistance of pneumococci causing NIPP in
adults in Portugal during a 13-year period, when the three
conjugate vaccines were available for children, and to compare




Case reporting and isolate collection were considered to be
surveillance activities and were exempt from evaluation by the
Review Board of the Faculdade de Medicina da Universidade de
Lisboa. The data and isolates were de-identified so that these were
irretrievably unlinked to an identifiable person.
Bacterial Isolates
Isolates were provided by a laboratory-based surveillance system
that includes 30 microbiology laboratories throughout Portugal.
These were asked to identify and send to our laboratory all
pneumococci causing infections. Although the laboratories were
contacted periodically to submit the isolates to the central
laboratory, no audit was performed to ensure compliance, which
may be variable in this type of study. After arrival, all isolates were
confirmed as S. pneumoniae by colony morphology and hemolysis
on blood agar plates, optochin susceptibility and bile solubility.
The isolates included in this study were recovered from adult
patients ($18 yrs) with a clinical diagnosis of pneumonia between
1999 and 2011. A total of 1300 isolates, 100 isolates randomly
chosen from among the isolates received in each of the 13 years of
the study were included. The total number of isolates submitted to
the central laboratory in each year was 161 in 1999, 184 in 2000,
319 in 2001, 282 in 2002, 265 in 2003, 341 in 2004, 338 in 2005,
392 in 2006, 525 in 2007, 601 in 2008, 473 in 2009, 519 in 2010
and 445 in 2011. We believe this reflects increasing compliance
with the surveillance activities with time. Only isolates recovered
from sputum, bronchial secretions or bronchoalveolar lavage were
considered. Isolates were not included when pneumococci were
simultaneously isolated from blood or another usually sterile
product, and when other potential bacterial pathogens besides
pneumococci were detected in the sample (such as Haemophilus
influenzae that was frequently detected). Only one isolate from
each patient in each year was considered. Among the 1300 isolates
selected, 103 (7.9%) were isolates from bronchoalveolar lavage
fluid.
Serotyping and Antimicrobial Susceptibility Testing
Serotyping was performed by the standard capsular reaction test
using the chessboard system and specific sera (Statens Serum
Institut, Copenhagen, Denmark). Serotypes were grouped into
conjugate vaccine serotypes, i.e., those included in PCV13
(serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 23F)
that comprise all the serotypes found in the lower valency vaccines
(PCV7: 4, 6B, 9V, 14, 18C, 19F, 23F; and PCV10: 1, 4, 5, 6B, 7F,
9V, 14, 18C, 19F, 23F), those included in PPV23 (all serotypes
included in PCV13 except 6A and serotypes 2, 8, 9N, 10A, 11A,
12F, 15B, 17F, 20, 22F and 33F), and non-vaccine serotypes
(NVT). The isolates that were not typable with any of the complete
set of sera were considered non-typable (NT).
Minimum inhibitory concentrations (MICs) for penicillin and
cefotaxime were determined using Etest strips (Biomérieux,
Marcy-L’Etoile, France). The results were interpreted using the
Clinical and Laboratory Standards Institute (CLSI) recommended
breakpoints prior to 2008 [20], as these allows the comparison
with previously published data. According to these criteria,
intermediate level penicillin resistance is defined as MIC 0.12–
1.0 mg/ml and high level resistance as MIC$2.0 mg/ml. Isolates
that fell into either one of these classes were designated penicillin
non-susceptible. Susceptibility to cefotaxime was defined as MIC#
1.0 mg/ml. The Kirby-Bauer disk diffusion assay was used to
determine susceptibility to levofloxacin, erythromycin, clindamy-
cin, chloramphenicol, trimethoprim/sulphamethoxazole, tetracy-
cline, vancomycin and linezolid, according to the CLSI recom-
mendations and interpretative criteria [21]. Macrolide resistance
phenotypes were identified using a double disc test with
erythromycin and clindamycin, as previously described [22].
The MLSB phenotype (resistance to macrolides, lincosamides and
streptogramin B) was defined as the simultaneous resistance to
erythromycin and clindamycin, while the M phenotype (resistance
to macrolides) was defined as non-susceptibility only to erythro-
mycin.
Statistical Analysis
Sample diversity was measured using Simpson’s index of
diversity (SID) and the respective 95% confidence intervals
(CI95%) [23]. To compare two sets of partitions the Adjusted
Wallace (AW) coefficients were calculated [24] using the online
tool available at www.comparingpartitions.info. Differences were
evaluated by the Fisher exact test with the false discovery rate
(FDR) correction for multiple testing [25] or the Chi-squared test,
and the Cochran-Armitage test was used for trends. A P,0.05 was
considered significant for all tests.
Results
Serotype Distribution
Serotype diversity was high [SID: 0.941, CI95%: 0.935–0.948],
with 57 different serotypes detected among the 1300 isolates. The
most frequent serotypes, which accounted for more than half of
the isolates, were serotypes: 3 (17.8%), 11A (6.7%), 19F (6.7%),
19A (5.2%), 14 (4.1%), 22F (4.1%), 23F (3.8%) and 9N (3.5%).
Serotype distribution in each of the studied years is represented in
Figure 1. We chose to represent an average of the yearly values
between 1999 and 2003, because it was shown previously that this
period corresponded to the years before an effect of children
vaccination with PCV7 was noted in the distribution of adult IPD
serotypes [14]. The yearly distribution on the 10 overall most
frequent serotypes between 1999 and 2003 is represented in Figure
S1. In spite of yearly variations, serotype diversity was high in all
studied years with the lowest SID detected in 2008 [SID: 0.901,
CI95%: 0.857–0.945] and the highest value found in both 2004 and
2009 [SID: 0.957, CI95%: 0.840–0.973].
The change in distribution of vaccine types along the study
years is shown in Figure 2 and Figure S2. The serotypes included
in PCV7 declined gradually from 31% in 1999–2003 to 11% in
2011 (Cochran-Armitage test of trend P,0.001). Among the
Streptococcus pneumoniae Pneumonia in Adults
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PCV7 serotypes, those that contributed mostly to this decline were
serotypes 6B (from 4.6% to 0%, Cochran-Armitage test of trend
P,0.001), 9V (from 3.2% to 0%, Cochran-Armitage test of trend
P,0.001) and 23F (from 6.6% to 1.0%, Cochran-Armitage test of
trend P,0.001). Despite fluctuations throughout the study period
in the number of isolates representing PCV13 and PPV23
serotypes, no consistent trend was noted. However, a decline of
the isolates expressing serotypes included in these vaccines, and a
consequent increase in the prevalence of NVTs, can be
distinguished between 2008 and 2009. This can be attributed to
a fall in serotype 3, from 28% to 9%, between these two years (P,
0.001, Figure 1). Although in subsequent years the proportion of
isolates expressing serotype 3 returned to values similar to those
found previously (Figure 1), this did was not reflected in an
increase in the proportion of isolates expressing PCV13 serotypes,
which remained close to 43% (Figure 2). In contrast, the decline in
the proportion of isolates expressing PPV23 serotypes noted in
2009 was not sustained, with the increases in the following years
bringing this value back into the range found in the previous
decade (Figure 2).
The distribution of the 10 most frequent serotypes found
between 1999 and 2011, stratified by age group, is shown in table
S1. The serotype distribution is similar for each of the age groups
considered (P = 0.398) and no significant associations, after
correction for FDR, could be found between specific serotypes
and age groups. When considering only the three last years of the
study, corresponding to the years immediately prior to PCV13
receiving approval for use in adults (2009–2011), the overall
proportion of isolates expressing serotypes included in the various
vaccines were 10.3% for PCV7, 43.7% for PCV13 and 66.0% for
PPV23. There was also no correlation between the proportion of
isolates causing NIPP included in the vaccines and the different
age groups (table S2).
Antimicrobial susceptibility
The proportion of isolates resistant to the tested antimicrobials
between 1999 and 2011 is summarized in table 1. Penicillin non-
susceptible pneumococci (PNSP) accounted for 18.5% of the
isolates (n = 241). Among these, 211 isolates (16.2%) expressed low
level resistance (MIC = 0.12–1 mg/mL) and 30 isolates (2.3%) high
level resistance (MIC$2 mg/mL). Considering the current CLSI
guidelines for parenteral penicillin in non-meningitis cases, where
high level resistance is defined as MIC$8 mg/mL and interme-
diate resistance as MIC$2 mg/mL [21], only 16 strains (1.2%)
would have been considered non-susceptible to penicillin, with
only one of these expressing high level resistance.
Erythromycin resistant pneumococci (ERP) accounted for
16.3% of the isolates (n = 212), with 84.0% (n = 178) of these
expressing the MLSB phenotype and 16.0% (n = 34) the M
phenotype. A total of 9.8% (n = 127) of the isolates were
simultaneously non-susceptible to penicillin and resistant to
erythromycin (EPNSP).
Resistance to levofloxacin was low overall (1.3%, n = 17), but
higher in the older age groups than in the youngest group
Figure 1. Serotype distribution of the isolates causing non-invasive pneumococcal pneumonia in adults in Portugal (1999–2011).
Only the overall 10 most frequent serotypes are shown. The other serotypes found between 1999 and 2011 were serotypes 6B, 7F and 15A (n = 32,
each), 23B (n = 30), 15B (n = 28), 10A (n = 27), 9V and non-typable (n = 26, each), 23A (n = 24), 1 (n = 22), 8 (n = 20), 16F (n = 19), 29 (n = 18), 4 (n = 17), 31
(n = 16), 34 (n = 15), 18C (n = 14), 17F and 33A (n = 13, each), 21 and 35F (n = 11, each), 15C and 35C (n = 10, each), 20 (n = 9), 12B and 17A (n = 8, each),
13, 25F and 25A/38 (n = 7, each), 7C and 28A (n = 5, each), 5 (n = 4), 11F, 18A and 19C (n = 3, each), 12A, 12F, 35A, 35B, 38 (n = 2, each) and 9L, 10F, 15F,
16A, 19B, 33F, 39 and 42 (n = 1, each). The value shown for 1999–2003 refers to the yearly average of the 500 isolates studied that were isolated in
these 5 years. This period was analyzed together since previously published IPD data indicated that these corresponded to a pre-PCV7 serotype
distribution [14].
doi:10.1371/journal.pone.0103092.g001
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(Table 1, 18–49 yrs versus 50–64 yrs, P = 0.014 and 18–49 yrs
versus $65 yrs, P = 0.012). No other significant associations with
age were found for the other antimicrobials tested. All isolates
were susceptible to vancomycin and linezolid.
The proportion of erythromycin and clindamycin resistant
isolates increased between 1999–2003 and 2011. Erythromycin
resistance increased from 8.0% to 18.0% (Cochran-Armitage test
of trend P,0.001) and clindamycin resistance increased from
Figure 2. Proportion of isolates expressing serotypes included in pneumococcal vaccines causing non-invasive pneumococcal
pneumonia in adults in Portugal (1999–2011). The value shown for 1999–2003 refers to the yearly average of the 500 isolates studied that were
isolated in these 5 years. This period was analyzed together since previously published IPD data indicated that these corresponded to a pre-PCV7
serotype distribution [14].
doi:10.1371/journal.pone.0103092.g002
Table 1. Antimicrobial resistance of the isolates responsible for non-invasive pneumococcal pneumonia in adults in Portugal,
stratified by age groups (1999–2011).
No. resistant isolates (%)a
[18–49] yrs [50–64] yrs $65 yrs Total
(n = 481) (n = 293) (n = 526) (n = 1300)
PENb 95 (19.8) 57 (19.5) 89 (16.9) 241 (18.5)
MIC90 0.25 0.38 0.25 -
MIC50 0.023 0.023 0.023 -
CTX 4 (0.8) 3 (1.0) 2 (0.4) 9 (0.7)
MIC90 0.19 0.125 0.094 -
MIC50 0.012 0.012 0.012 -
LEV 1 (0.2) 6 (2.0) 10 (1.9) 17 (1.3)
ERY 76 (15.8) 54 (18.4) 82 (15.6) 212 (16.3)
CLI 66 (13.7) 44 (15.0) 68 (12.9) 178 (13.7)
CHL 17 (3.5) 12 (4.1) 22 (4.2) 51 (3.9)
SXT 89 (18.9) 46 (15.7) 84 (16.0) 219 (16.8)
TET 61 (12.7) 42 (14.3) 63 (12.0) 166 (12.8)
aPEN – penicillin; CTX – cefotaxime; LEV – levofloxacin; ERY – erythromycin; CLI – clindamycin; CHL – chloramphenicol; SXT – trimethoprim/sulphamethoxazole; TET –
tetracycline. All isolates were susceptible to vancomycin and linezolid.
bNon-susceptibitily to penicillin was determined using the CLSI breakpoints prior to 2008 [20].
doi:10.1371/journal.pone.0103092.t001
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7.0% to 15.0% (Cochran-Armitage test of trend P = 0.004). No
other significant changes were noted for the other antimicrobials
tested.
There was an association between serotype and antimicrobial
resistance. The AW for serotype and PNSP was 0.588 (CI95%:
0.541–0.634) and the AW for serotype and ERP was 0.489 (CI95%:
0.419–0.558). Table 2 shows the serotypes that presented at least
10 PNSP and ERP isolates, respectively. Among the major
serotypes expressed by PNSP, only serotype 19F was not
significantly associated with PNSP. Among the major serotypes
expressed by ERP, only serotypes 23F and 6C were not
significantly associated with ERP. The PCV7, PCV13 and
PPV23 serotypes accounted for 56.0%, 70.5% and 69.7% of
PNSP, respectively, and 42.9%, 60.8% and 66.5% of ERP,
respectively.
Discussion
Serotype 3 was the most important serotype in NIPP in adults in
Portugal. This serotype was the most frequently detected in all
studied years, with the exception of 2009, when it ranked third
(Figure 1). A predominance of serotype 3 was also found in two
studies that focused on the serotype distribution of pneumococcal
pneumonia isolates [5,26], and this serotype was among the most
frequent in two recent studies using urinary antigen detection
assays to diagnose pneumococcal pneumonia [7,27], although
these last studies included both NIPP and bacteremic pneumonia.
In Portugal, serotype 3 is not only a leading cause of NIPP but also
of IPD, as can be seen in Figure S3, showing the distribution of the
most frequently detected serotypes immediately prior to the
licensure of PCV13 for adult immunization (2009–2011).
Although both IPD and NIPP were characterized by a high
serotype diversity (for NIPP SID = 0.943, CI95%: 0.932–0.955; and
for IPD SID = 0.942, CI95%: 0.937–0.946; considering 2009–
2011), the actual serotype distribution is quite different (Figures 3,
Figure S3 and Table S3). Among the most frequent serotypes,
accounting for half of the characterized isolates in 2009–2011,
only two serotypes were common to both NIPP and IPD, which
were serotypes 3 and 19A (Figure S3). When comparing the
serotype distribution, serotypes 6A, 11A, 15C, 19F and 23B were
significantly more abundant among NIPP isolates, whereas
serotypes 1, 4,7F and 14 were significantly more abundant among
IPD isolates (Figure 3 and Table S3). These four serotypes,
together with serotype 3, were already shown to have an enhanced
invasive disease potential in a study evaluating the serotypes and
clones circulating in Portugal [8]. On the other hand, serotypes
6A, 11A and 19F were associated with carriage [8], suggesting
their lower invasive disease potential, consistent with the
association with NIPP determined here (Figure 3 and Table S3).
A recent study described the serotype distribution among
isolates recovered in 2011 causing bacteremic and non-bacteremic
pneumonia in adults in Denmark [5]. When considering only the
isolates recovered in 2009–2011 in Portugal, the serotype
distribution is, perhaps surprisingly, remarkably similar in both
studies. Among the differences are the more significant fractions of
non-typable isolates among NIPP and of serotype 1 isolates in
bacteremic pneumonia in Denmark relative to Portugal. Serotype
1 was always an important serotype among isolates causing IPD in
both children and adults in Portugal, but its significance has
Table 2. Serotype distribution of PNSP and ERP causing non-invasive pneumococcal pneumonia in adults in Portugal (1999–2011).
Serotypea No. of resistant isolates (%) OR (CI95%) P-value
b
PEN 23F 39 (16.2) 12.6 (6.2–27.7) ,0.001
14 37 (15.4) 8.1 (4.3–15.9) ,0.001
19A 28 (11.6) 2.3 (1.3–3.9) 0.002
15A 27 (11.2) 18.2 (6.8–61.3) ,0.001
19F 27 (11.2) 1.4 (0.8–2.3) 0.193
9V 23 (9.5) 25.5 (7.6–133.7) ,0.001
6C 18 (7.5) 3.0 (1.5–6.2) 0.001
Othersc 42 (17.4) - -
ERY 19F 37 (17.5) 3.4 (2.1–5.4) ,0.001
19A 31 (14.6) 3.7 (2.2–6.4) ,0.001
15A 28 (13.2) 31.9 (11.0–126.2) ,0.001
14 21 (9.9) 2.8 (1.5–5.1) ,0.001
6B 15 (7.1) 3.7 (1.7–8.0) ,0.001
23F 14 (6.6) 1.6 (0.8–3.1) 0.151
33A 10 (4.7) 13.8 (3.5–79.0) ,0.001
6C 10 (4.7) 1.5 (0.6–3.3) 0.296
NTd 10 (4.7) 2.6 (1.0–6.1) 0.025
Otherse 36 (17.0) - -
aOnly the serotypes that presented at least 10 non-susceptible isolates are shown.
bSignificant P-values after FDR correction are highlighted in bold.
cOther serotypes found among PNSP: 6B (n = 8), non-typable (n = 7), 6A and 29 (n = 5, each), 23B and 24F (n = 3, each), 7C (n = 2), 1, 3, 4, 11A, 15B, 15F, 22F, 23A, 35A
(n = 1, each).
dNT – non typable.
eOther serotypes found among ERP: 9V and 11A (n = 4, each), 3, 15B, 22F, 23A, 24F (n = 3, each), 6A (n = 2), 1, 7F, 8, 9N, 15F, 16F, 17F, 23B, 29, 33F and 35F (n = 1, each).
doi:10.1371/journal.pone.0103092.t002
Streptococcus pneumoniae Pneumonia in Adults
PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e103092
Streptococcus pneumoniae Pneumonia in Adults
PLOS ONE | www.plosone.org 6 July 2014 | Volume 9 | Issue 7 | e103092
declined in recent years [13,15,19,28]. This change cannot be
attributed entirely to the use of higher valency vaccines, such as
PCV13, although vaccination was potentially a contributing factor
[19,28]. Another important difference is the persistence of
serotype 14 isolates among both NIPP and IPD in Portugal, in
contrast to Denmark where this serotype was found at a lower
frequency [5]. Serotype 14 was already included in PCV7, and
continued vaccine use could be expected to significantly reduce its
prevalence. A lower and more protracted vaccine uptake in
Portugal compared to Denmark, together with a higher antibiotic
consumption, could contribute to the differences observed
between the two countries.
In previous studies, we showed that immunization of children
with PCV7 resulted in the decline of PCV7 serotypes as causes of
adult IPD [13,19]. In the present study, we show that a decline of
PCV7 serotypes also occurred among isolates causing NIPP in
adults. However, while in IPD this decline was abrupt, occurring
between 2004 and 2005, in NIPP this decline was gradual and
occurred over the entire post-PCV7 period (Figure 2 and Figure
S2). The proportion of isolates expressing PCV7 serotypes in the
most recent years of the study was different between NIPP and
IPD (10.3% versus 19.0% in 2009–2011, P,0.001, Figure 3).
Taken together, the isolates expressing PCV13 serotypes also
declined in IPD and in NIPP, a change that was observed from
2008 onwards for both disease presentations. However, again
there were important differences. While in IPD this decline
occurred from 2008 to 2011 and was mostly due to decreases in
serotypes 1 and 5, in NIPP this decline occurred between 2008
and 2009 and was predominantly caused by a decrease in serotype
3. In neither case can we attribute these changes to the
introduction of PCV13 in Portugal, since this vaccine only
became available for children in the beginning of 2010 and
received an indication for adults in the beginning of 2012. In
NIPP, one possible explanation for the change observed could be
the H1N1pdm09 pandemic that occurred between 2009 and
2010. Individuals infected by influenza are at high risk of
developing secondary bacterial infections, especially with pneu-
mococci [29]. Consistent with the hypothesis that influenza
allowed the emergence of multiple serotypes as causes of NIPP,
the decrease of serotype 3 from 2008 to 2009 was accompanied by
an increase in serotype diversity.
Another remarkable difference between NIPP and IPD is the
proportion of isolates that expresses serotypes included in the
available vaccine formulations with an adult indication. When
analyzing data from 2009 to 2011, we found that the number of
IPD cases that could have been potentially prevented by PCV13
and PPV23 was 59%, and 80%, respectively [19], while the
proportion of isolates expressing these serotypes was only 44% and
66%, respectively, among our collection of NIPP isolates. The
higher proportion of vaccine types among IPD isolates was also
documented in Denmark [5]. The efficacy of the conjugate
vaccines is well established and adults could now benefit directly
from PCV13 use. However, according to our sample more than
half of NIPP cases could not have been prevented by vaccination
with PCV13.
In the present study we could not find any significant
associations between serotypes and age groups. This is in contrast
to our previous studies with invasive isolates, where serotypes 3
and 19A were associated with older patients and serotypes 1 and 8
were associated with younger patients [19]. However, if we do not
consider the correction for multiple testing, serotype 3 was more
frequent in older adults than in the youngest (14% in 18–49 yrs
versus 20% in $50 yrs, P = 0.005, Table S1). The lack of
association for the other three serotypes with age is likely the
result of their small numbers in our NIPP sample, particularly in
what concerns serotypes 1 and 8.
A high proportion of the resistant isolates recovered between
1999 and 2011 are of serotypes included in PCV7 (Table 2),
accounting for 56% of PNSP and 43% of ERP in the entire study
period. Unlike what could have been expected, the introduction of
PCV7 in Portugal did not reduce the proportion of resistant
isolates, neither in NIPP nor in IPD [14,19]. Actually, for both
presentations there was an increase in ERP between 1999 and
2011, and for IPD there was also an increase in PNSP. However,
when we considered the most recent data (2009 to 2011) we found
that only 22% of PNSP and 26% of ERP causing NIPP,
represented serotypes included in PCV7. This means that resistant
isolates expressing serotypes that are not included in PCV7 have
emerged and expanded in the post-PCV7 period.
When considering the entire study period, antimicrobial
resistance among NIPP isolates was similar to the values reported
recently for IPD [19] (Table 1). Given the association between
serotype and antimicrobial resistance, and the different serotype
distributions between NIPP and IPD, how can we explain the
similar overall resistance? For the most part, the explanation can
be found in the more gradual decrease of resistant PCV7
serotypes, albeit to a lower level, in NIPP when compared to
IPD. This was accompanied by the rise of a different set of
serotypes including resistant isolates that are not included in
PCV7, resulting in similar overall resistance levels. Resistance
among NIPP isolates is partly due to the proliferation of resistant
serotype 19A isolates, probably representing a lineage which has
been expanding as a cause of IPD in children and adults [19,30],
and that became the single most important serotype among PNSP
and ERP in the last three years of the study. This was
accompanied by increases in serotypes including resistant isolates
not represented in PCV13, such as serotypes 6C, 15A, 29, 33A, as
well as non-typable isolates, each including n.5 PNSP or ERP
during the entire study period (table 2).
The major limitation of this study is that we do not know if
blood cultures were performed for all patients, and so we cannot
exclude the possibility that some of the isolates attributed to NIPP
were in fact reflecting cases of invasive disease. However, the
distinct serotype distribution between IPD and NIPP and the
similar distribution found in this study and among isolates causing
NIPP in Denmark in a similar period [5], in spite of the different
epidemiological contexts, strongly argues against a significant bias
in our sample. Another possible confounder could be that a
fraction of our isolates are reflecting colonization and not
infection. Again we consider this unlikely. The fluids included
are not present in healthy subjects (sputum and bronchial
secretions) or are not obtained unless there is a strong suspicion
of pneumonia (bronchoalveolar lavage). The participating labora-
tories used criteria to exclude low quality samples, which would be
Figure 3. Serotype distribution of the isolates causing non-invasive pneumococcal pneumonia and invasive pneumococcal disease
in adults in Portugal (2009–2011). Data from IPD were published previously [19]. Serotypes associated with NIPP or IPD are marked by asterisks.
The odds ratio was used to measure the association between serotype and disease presentation and only significant values (P,0.05) after FDR
correction are indicated. The P values for the serotypes associated with NIPP were: P = 0.001 for 19F, P = 0.007 for 6A, P = 0.004 for 11A, P = 0.001 for
15C, P,0.001 for 23B. The P values for the serotypes associated with IPD were: P = 0.007 for 4, P,0.001 for 14, P,0.001 for 1 and P,0.001 for 7F.
doi:10.1371/journal.pone.0103092.g003
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more likely to reflect upper airway microbiota. Finally, adult
colonization is known to be rare [31] and would be therefore
unlikely to account for a significant fraction of the isolates. Taken
together, these arguments support a role for the pneumococci
analyzed in infection and not asymptomatic colonization. The
decision to collect specimens for microbiological analysis was the
responsibility of the attending physician that did not receive
specific guidelines. We are not aware of significant changes in
practice during the study period, although differences between the
participating centers may exist. However, since these are expected
to be minor and stable during the study period we do not feel these
constitute a significant source of bias.
In this study, we found a different serotype distribution and
dynamics in NIPP and IPD in the same population. This was
highlighted by the fact that the potential coverage of the currently
available pneumococcal vaccines with an adult indication is lower
in NIPP than in IPD. The distinct dynamics of NIPP, the
availability of PCV13 for adults together with the issues raised
regarding the efficacy of PPV23 in the context of NIPP, and the
fact that NIPP is a frequent cause of morbidity and mortality
among adults, all underscore the relevance of considering the use
of PCV13 in adults. However, the expected herd protection
conferred by vaccinating children with PCV13 could reduce the
benefits of direct adult vaccination. We documented here ongoing
changes in the serotypes causing NIPP that are potentially due to
long-term PCV7 use, but there is uncertainty regarding the
ultimate reduction in vaccine serotypes one can expect from this
effect, as well as regarding the kinetics of such a decline.
Continued surveillance is essential to evaluate the changing
potential benefits of direct adult vaccination.
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Ana Rodrigues, Isabel Nascimento (Hospital Garcia de Orta, Almada),
Elmano Ramalheira, Fernanda Bessa, Raquel Diaz (Hospital Infante D.
Pedro, Aveiro), Isabel Vale, Ana Carvalho, José Miguel Ribeiro (Hospital
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Lurdes Magalhães, Helena Rochas, Anabela Silva (Instituto Nacional de
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